RxDoctor Payments Data

Fred Mendoza, MD

Internal Medicine · Green Valley, AZNPI 1316935042

Payments from drug & device makers

$10,546in general payments, 2019–2025

Across 641 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • GSK$2K
  • AstraZeneca$899
  • Novo Nordisk$888
  • AbbVie$574
  • Astellas Pharma US Inc$522
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$10,27697%
  • Education$2703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,546 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$593,399
Medicare patients
824
Services billed
17,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$274,900
EliquisApixaban151$199,065
MounjaroTirzepatide89$133,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$72,383
JardianceEmpagliflozin37$59,423
XareltoRivaroxaban34$54,700
TrulicityDulaglutide38$50,820
JanuviaSitagliptin Phosphate26$43,925
LinzessLinaclotide29$37,979
ProliaDenosumab18$32,005
FarxigaDapagliflozin Propanediol22$30,036
GemtesaVibegron29$28,353
MyrbetriqMirabegron19$24,698
Tresiba Flextouch U-100Insulin Degludec21$15,582
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$888$274,900171 claims
PfizerEliquis$311$199,065151 claims
Lilly USA, LLCMounjaro, Trulicity$362$184,438127 claims
GSKTrelegy Ellipta, Breo Ellipta$1,532$82,84791 claims
Boehringer IngelheimJardiance$285$59,42337 claims
Johnson & JohnsonXarelto$437$54,70034 claims
MerckJanuvia$120$43,92526 claims
AstraZenecaFarxiga, Symbicort$899$40,30862 claims
AbbVieLinzess$574$37,97929 claims
AmgenProlia$1,607$32,00518 claims
Sumitomo Pharma America, Inc.Gemtesa$364$28,35329 claims
Astellas Pharma US IncMyrbetriq$522$24,69819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Green Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →